Webinar: Safety of acrylate monomers, metals, and other materials used in medical device development

Join our upcoming free webinar to explore the effective utilization of in vitro methods for safety assessment of materials during product development of Medical Devices. We will discuss recent advancements in in vitro methods for assessing the endpoints of skin irritation and skin sensitization. Learn how to integrate these assessments into your product development process […]

Webinar: Spotlight on Difficult-to-Test samples

Join our upcoming webinar to explore the recent advancement in GARD® for Skin Sensitization assessment, with a specific focus on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. Our skin sensitization experts will address challenges posed by various Difficult-to-Test substances, discussing the applicability domain of […]

Webinar: Advancing NAMs for Skin Sensitization Testing

Spotlight on Applicability Domain, Quantitative Potency Assessment and Medical Devices In case you missed SenzaGen’s poster presentations and scientific session at this year’s SOT, we are pleased to offer you a new opportunity to participate on April 23, 2024! In this webinar Dr Andy Forreryd, SenzaGen's in vitro toxicology expert, will summarize the latest GARD data from industry collaborations: […]

Webinar: Meta-analysis of GARD® data, 200+ chemicals

Spotlight on in vitro quantitative assessment of skin sensitizing potency. Join our upcoming webinar to explore the recent advancement in GARD® for quantitative assessment of skin sensitizing potency. This session will present a meta-analysis of GARD® data covering over 200 chemicals, including three blinded datasets generated in collaboration with industry partners. These data will demonstrate […]

Webinar: Advancing NAMs for Skin Sensitization Testing

Spotlight on Point-of-Departure, Challenging Substances, and Active Ingredients We invite you to join our upcoming webinar, where industry leaders from Lundbeck, Unilever, and Cargill, along with experts from SenzaGen will explain the latest advancements in skin sensitization testing. Join us as we explore the latest data from our GARD® platform on skin sensitization and gain […]

Webinar: In vitro skin sensitization testing: Ensuring conclusive results for challenging samples

Join us for a special re-run of our popular GARD® webinar to explore the recent advancement in Skin Sensitization testing, focusing on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. Our skin sensitization experts will address challenges posed by various "Difficult-to-Test" substances, discussing the applicability […]

Webinar: Overcoming the challenges of testing Natural Extracts with GARD technology

Join SenzaGen and industry leaders from Clarins and Bic Skin Creative for an in-depth webinar on using GARD® assays for skin sensitization testing. Learn how this innovative technology overcomes the unique challenges of testing complex Natural Extracts, which often fall outside the scope of traditional methods in OECD 442E Test Guidelines. Through case studies, we will showcase […]

Webinar: Regulatory updates & industry perspectives on NAMs for Medical Device Safety

Join us for an insightful webinar on the evolving role of New Approach Methodologies (NAMs) in regulatory biological safety assessments and how they can be used to help develop safe materials in the pre-regulatory space. With shifting standards and increasing adoption of NAMs, understanding their impact is more critical than ever. In this webinar, Dr […]

Webinar: Scientific highlights from 2025 SOT

Advancing NAMs for Skin Sensitization Testing: Natural Extracts, Medical Devices and Potency Join our upcoming webinar, where SenzaGen’s expert and guest speakers from dōTERRA and Risk Science Consortium will share insights and case studies on the use of New Approach Methodologies (NAMs) for skin sensitization assessment. We’ll present the latest GARD® data from our research […]